ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2025
The Composite Health Risk Assessment Model (CHARM) Predicts Overall Mortality and Relapse, But Not Non-Relapse Mortality, in Adults Following Unrelated Single-Unit Cord Blood Transplantation
Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nutritional status, dietary antioxidant capacity, and dietary diversity in patients with newly diagnosed hematological malignancies: a case-control study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Methodological Concerns Regarding the Validation of the CHARM Score for Cord Blood TransplantationTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Concerns about excessive non-relapse mortality (NRM) are a major issue following allogeneic hematopoietic cell transplantation (HCT). Although the HCT-Specific Comorbidity Index (HCT-CI) was established as a stratification model for NRM following allogeneic HCT, the Composite Health Risk Assessment Model (CHARM) score was also developed to predict the risk of NRM and overall mortality following allogeneic HCT from adult donors, particularly in older patients. The CHARM score has been shown to predict these outcomes better than the HCT-CI alone. However, the prognostic value of the CHARM score has not been validated in adult patients undergoing unrelated single-unit cord blood transplantation (CBT). This study aimed to address that gap in the research. Materials and Methods: We retrospectively validated the impact of the CHARM score on transplant outcomes in 321 adults who underwent unrelated single-unit CBT at our institution. Results: In univariate analysis, a higher CHARM score was significantly associated with worse overall mortality (p<0.001), higher relapse (p=0.007), and NRM (p=0.048). In multivariate analysis, the rates of overall mortality (hazard ratio [HR]: 1.56, 95% confidence interval [CI]: 1.06-2.29, p=0.022) and relapse (HR: 1.71, 95% CI: 1.09-2.69, p=0.020) were significantly higher in patients with higher CHARM scores, but NRM was not (HR: 1.17, 95% CI: 0.68-1.99, p=0.560). The detrimental effects of higher CHARM scores on overall mortality and relapse compared to lower CHARM scores were observed in subgroups of patients with high and very high risk, as defined by the refined Disease Risk Index. Conclusion: In contrast to previous research, this study revealed that the CHARM score was able to predict overall mortality and relapse, but not NRM, in adults undergoing single-unit CBT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.